Really proud of my great unige Ospedale San Martino Genova friend Andrea Boutros, presenting at #ESMO24 results of his work performed during his fellowship at Melanoma Institute Australia MIA Institut! 🇦🇺 OncoAlert Francesco Spagnolo Matteo Lambertini, MD PhD Lucia Del Mastro

NEOCheck-Ray: does adding #durvalumab and SBRT to neoadjuvant chemotherapy improves pCR in Lum B #ebc ? Alex De Caluwe Institut Jules Bordet Instituut OncoAlert  #ESMO24 #ESMOAmbassadors

#ESMO24 proffered eBC session Neo-CheckRay trial presented by Alex De Caluwe demonstrated numerically ⬆️ RCB0/1 with Durvalumab + Oleclumab + SBRT during neoadjuvant tp in high-risk, HR+ eBC. 🔎 Impressive responses with ICIs + SBRT in PDL1 neg disease! OncoAlert Institut Jules Bordet Instituut

#ESMO24 proffered eBC session Pts with stage I-II, node negative, TILs ≥50% TNBC treated with nivo+ipi or nivo+rela pCR rates: ➡️ 5/15 (33%) in the nivo/ipi cohort ➡️ 7/15 (47%) in the nivo/real cohort Intriguing results for a chemo-sparing regimen in early TNBC! OncoAlert

#ESMO24 proffered eBC session Updated results of #NATALEE trial at 4y median fup. ⬆️ iDFS from 83.6% to 88.5% with 3y RIBO to adj ET ➡️ Consistent results also in stage II and node-negative diseases 🔄 Immature OS data OncoAlert

☢️iSBRT demonstrated promising activity in #MammaPrint high risk Luminal B #BreastCancer in combination with neo-adjuvant chemo-immuno to prime the immune response 🔥 ➡️especially in PD-L1 negative tumors : ⬆️pCR from 3.8% to 34.6 & 33.3% 👏Alex De Caluwe Institut Jules Bordet Instituut

#ESMO24 Terrific updates by Roberto Borea from Università di Genova AIOM ESMO - Eur. Oncology 🧬 CTCs have a role in early detection of recurrence of high-risk #BreastCancer #ebc 💪🏽 OncoAlert Oncoinfo OncoDaily

I couldn’t be more proud of being awarded as one of the ESMO - Eur. Oncology Clinical Research Fellow 2024, which will allow me to continue my research among Ospedale San Martino Genova and Institut Jules Bordet Instituut! Deeply grateful to Matteo Lambertini, MD PhD and Evandro de Azambuja, MD, PhD for supporting me and this research proposal! 🙏🏼

👏👏👏

Superb presentation of the Rome trial by Andrea Botticelli during the Presidential Session III at #ESMO24 🔝🇮🇹 congratulations 👏🏻 Andrea

🚨in the future of oncology with Andrea Botticelli presenting ROME trial outcome! —> using personalized target and immuno therapy in pretreated metastatic solid tumor patients improves ORR and PFS! 📈 #ESMO24 #Italianeffort ESMO - Eur. Oncology OncoAlert Sapienza Università di Roma

Honored to present our center's data on the issue of diagnostic delay in patients affected by lung cancer. Grateful to Professor Carlo Genova for the guidance in evaluating perspectives different from the usual. ESMO - Eur. Oncology OncoAlert Ospedale San Martino Genova #ESMO24

Now out in ESMO Open our study on characteristics and clinical outcomes of breast cancer in a 🌎cohort of 4,628 young BRCA carriers🧬 according to tumor histology ➡️Low incidence of lobular, having higher disease stage and more BRCA2️⃣ PVs OncoAlert authors.elsevier.com/sd/article/S20…

Presidential session IV at #ESMO24: Important and practice-changing updates on zone defense and rotating goalkeepers 🔄⚽️😂 👇🏼👇🏼👇🏼

Thank you so much Matteo Lambertini, MD PhD for always encouraging me to do always better and for supporting our project from the beginning! It’s an honor for me representing our great Università di Genova team in this ESMO - Eur. Oncology Fellowship.. can’t wait for several new projects together 🇮🇹🫱🏻‍🫲🏽🇧🇪

Excited to be part of this study on young mBRCA patients with BC! Early Lobular BC: 🧬 more linked to BRCA2 🔪more mastectomies 💉less chemo > After 7.8y, no significant differences in survival were seen between cancer subtypes! #breastcancer Matteo Lambertini, MD PhD Elisa Agostinetto

#ESMO24 broke all records... and now a family of >40.000 members ESMO - Eur. Oncology

MIA Medical Oncology Fellow Dr Andrea Boutros Andrea Boutros presented MIA driven research at #ESMO24. Andrea provided updated results from #MATCHMEL trial which involved molecular profiling & matched targeted therapy for advanced #melanoma patients. bit.ly/3XPGcnf ESMO - Eur. Oncology

U.S. FDA has just approved adjuvant ribociclib based on the results of the NATALEE trial presented at #ESMO24 In Barcelona I discussed the results of NATALEE and other trials presented at ESMO with MediMix 👇🏻 OncoAlert

Always a pleasure to join the #GIM Annual Meeting! Great opportunity to foster collaboration among academic institutions in Italy. Excited to launch GIM29 - GIMOMIC together with Dr. Chiara Benvenuti. Thankful to the whole GIMGroup for the opportunity to realize this project!